ImaginAb, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Inglewood CA United States (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2013
NCT01923727
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

ImaginAb, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

89zr df-iab2m (4 trials)

azd8853 (1 trial)

iab22m2c (7 trials)

Drugs in Phase 1 Trials (4)

asp8374 (1 trial)

bempegaldesleukin (1 trial)

cemiplimab (libtayo) (1 trial)

nivolumab (opdivo) (1 trial)

Drugs in Other Trials (1)

124i-psca (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 1)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 8